New PREVUE-VALVE Data Underscore Growing and Underserved TR Patient Population

Tricuspid regurgitation (TR) is the most prevalent valvular heart disease, yet it remains one of the most undertreated.
This disconnect between disease burden and available treatment options is becoming increasingly visible as new epidemiological data emerge.

The PREVUE-VALVE study, one of the largest contemporary population-based assessments of valvular heart disease in older adults, provides a comprehensive and updated view of valve disease prevalence in the United States. Its findings underscore the scale and urgency of the TR challenge.

Key insights from the PREVUE-VALVE study

PREVUE-VALVE evaluated the prevalence of clinically meaningful valvular heart disease in an aging population, offering important nuance beyond earlier, smaller studies. One of its most notable findings is the high prevalence of tricuspid regurgitation, which exceeds that of other valve diseases and increases sharply with age.

As life expectancy rises, the number of patients affected by TR is projected to grow substantially over the coming decades. The study highlights that while valvular heart disease overall increases with age, TR shows one of the steepest age-related prevalence curves, signaling a rapidly expanding patient population.

Despite this high prevalence, the vast majority of TR patients today are treated conservatively. Surgical intervention is often delayed or avoided due to procedural risk, patient frailty, or late referral, leaving approximately 97% of patients without an interventional treatment option.

A widening gap between prevalence and treatment

Historically, innovation in valvular heart disease has focused predominantly on aortic and mitral pathologies. While this has led to major advances, TR has remained comparatively underserved, despite its association with reduced quality of life, increased hospitalizations, and poorer long-term outcomes.

The PREVUE-VALVE data reinforce that TR is not a niche condition, but a large and growing public health challenge. The combination of high prevalence, aging demographics, and limited therapeutic access creates a structural gap in care—one that demands new, scalable treatment approaches.

Tripair™: addressing an unmet clinical need

At Coramaze Technologies, this gap is exactly what Tripair™ is designed to address. Tripair™ is being developed as a minimally invasive, scalable interventional solution aimed at expanding treatment access for patients with tricuspid regurgitation who today go untreated.

By focusing on procedural simplicity, safety, and real-world applicability, Tripair™ seeks to enable earlier intervention and broader adoption, aligning technological innovation with the clinical realities highlighted by PREVUE-VALVE.

Presenting at LSI USA ’26

Against this backdrop, Coramaze Technologies has been selected to present at LSI USA ’26, taking place March 16–20, 2026 in Dana Point, California.

Our CEO, Jochen Reinöhl, MD, MSc, will take the stage to discuss how emerging epidemiological insights—such as those from the PREVUE-VALVE study—are shaping the future of tricuspid regurgitation treatment, and how Tripair™ is being developed to translate unmet clinical need into a practical interventional solution.